E

Energenesis Biomedical Co Ltd
TWSE:6657

Watchlist Manager
Energenesis Biomedical Co Ltd
TWSE:6657
Watchlist
Price: 40.95 TWD 1.11% Market Closed
Market Cap: 3.6B TWD

Energenesis Biomedical Co Ltd
Investor Relations

Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.

Show more
Loading
6657
Taiwan Weighted Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Jen-yi Chiu
Co-Founder & Chairman
No Bio Available
Dr. Han-min Chen
Co-Founder, Vice Chairman & GM
No Bio Available
Ms. Pei-chao Chen
Director of Accounting
No Bio Available
Mr. Ming-tsan Chiang
VP, Corporate Governance Officer & Director of the General Administrative Division
No Bio Available

Contacts

Address
TAIPEI
Taipei City
6F-3, No.21, Lane 583, Ruiguang Road
Contacts